There have been little progress for more than a decade in treating chronic heart failure, in which the heart fails to pump blood around the body.
The study compared LCZ696 to an older drug already known to improve survival.
The European Society of Cardiology (ESC)
has flagged the PARADIGM-HF trial, reflecting the pressing need to find better treatments than the current line-up of the old generic medicines .In a study - the largest ever undertaken in heart failure and involving more than 8,400 patients -LCZ696 was tested against enalapril , a so - called ACE inhibitor drug.
Patients who took LCZ696 were 20 % less likely than those on enalapril to die of cardiovascular causes and were also 21percent less likely to be admitted to hospital,according to the results presented at the conference of the European Society of Cardiology.
The new drug developed by Switzerland based 'Novartis' .The drug could be on the market by 2015.
Comments
Post a Comment